The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
51
One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
This is the placebo control
Site 03
Encino, California, United States
Site 02
San Diego, California, United States
Site 01
San Diego, California, United States
Site 04
Rolling Meadows, Illinois, United States
Clinician Submental Fat Scale (CSFS)
Change from Baseline after final treatment. CSFS is a 5 point scale, with a higher score indicating higher severity
Time frame: 24 weeks after final injection treatment
Patient Submental Fat Scale (PSFS)
Change from Baseline after final treatment. PSFS is a 5 point scale, with a higher score indicating higher severity
Time frame: 24 weeks after final injection treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.